Log In
Print this Print this

Colonic-release linaclotide

  Manage Alerts
Collapse Summary General Information
Company Ironwood Pharmaceuticals Inc.
DescriptionColonic-release formulation of linaclotide, a guanylate cyclase C (GCC; GUCY2C) agonist
Molecular Target Guanylate cyclase C (GCC) (GUCY2C)
Mechanism of ActionGuanylate cyclase C agonist
Therapeutic ModalityPeptide
Latest Stage of DevelopmentPhase II
Standard IndicationIrritable bowel syndrome
Indication DetailsTreat irritable bowel syndrome with constipation (IBS-C)
Regulatory Designation
PartnerAllergan plc;
Almirall S.A.;
Astellas Pharma Inc.;
AstraZeneca plc

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today